Nano-enabled delivery of Himalayan plant bio-actives for controlling implant-associated inflammation and fibrosis
Аннотация
This review provides a comprehensive analysis of nano-enabled Himalayan phytotherapeutics targeting implant-associated inflammation and fibrotic capsule formation. Mechanistic synthesis reveals that key bioactives—including Withaferin A, Picrosides I and II, Mangiferin, and Emodin—modulate chronic inflammatory and fibrotic cascades by inhibiting TLR4/NFkB and NLRP3 inflammasome activation, restoring NFE2L2-mediated antioxidant defenses, suppressing TGF-β 1/Smad2/3 signaling, and downregulating α-smooth muscle actin α-SMA) stress fiber formation, collagen type I/III deposition, and matrix metalloproteinase-driven extracellular matrix remodeling. Nanocarrier platforms, including polymeric nanoparticles, liposomes, solid lipid nanoparticles, and bioactive hydrogel coatings, significantly enhance phytochemical bioavailability, localized surface retention, and sustained release at biomaterial interfaces. Evidence-tiered evaluation demonstrates robust preclinical efficacy for well-characterized bioactives in rodent foreign body reaction and wound models, whereas evidence for secondary metabolites remains largely extrapolated from general non-implant disease paradigms or preliminary in silico predictions. Computational approaches, including network pharmacology, molecular docking, multi-omics, and artificial intelligence, effectively prioritize bioactive leads and optimize formulation dynamics, but require downstream empirical validation. Critical translational bottlenecks include botanical batch-to-batch composition variability, extract standardization, nanomanufacturing scale-up under Current Good Manufacturing Practice guidelines, long-term degradation and toxicological safety at the implant interface, and complex combination product regulatory approval pathways. Direct evidence for the efficacy and long-term safety of Himalayan plant-derived nanoformulations in implant-associated inflammation and fibrosis remains limited, highlighting the need for standardized formulations, mechanistically rigorous preclinical studies, appropriate implant models, long-term safety assessment, and well-designed clinical investigations.